Your session is about to expire
← Back to Search
Diagnostic Test
BioFire® Respiratory Panel 2.1-EZ for Viral Infections (URGENT Trial)
N/A
Waitlist Available
Led By Andrew Meltzer, MD
Research Sponsored by Andrew Meltzer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Clinically stable
Must present with one symptom of respiratory illness (e.g., cough, sneezing, runny or stuffy nose, sore throat, headaches, muscle aches, trouble breathing, shortness of breath, and/or fever).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7 after enrollment
Awards & highlights
URGENT Trial Summary
This trial is testing a rapid PCR test to see if it can improve patient and provider-reported outcomes for people with symptomatic upper respiratory infections.
Eligible Conditions
- Viral Infections
- Acute Respiratory Infection
- Common Cold
URGENT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You are in good overall health with no major health issues.
Select...
You need to have at least one symptom of a respiratory illness, such as cough, sneezing, runny nose, sore throat, headache, muscle aches, difficulty breathing, shortness of breath, or fever.
URGENT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 7 after enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 7 after enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Missed time at work or school
Need for additional diagnostic tests by participants family members / close contacts
Need for additional diagnostic tests by patient
+4 moreURGENT Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: BioFire® Respiratory Panel 2.1-EZExperimental Treatment1 Intervention
EXP group will receive the BioFire RP2.1-EZ panel, designed to test for a variety of bacterial and/or viral causes for illness
Group II: Standard of CareActive Control1 Intervention
Standard care procedures are essentially yes/no to patient having SARS-COV-2, the SC group will receive the standard nasal swab used in the IPCs.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BioFire® Respiratory Panel 2.1-EZ
2022
N/A
~360
Find a Location
Who is running the clinical trial?
Andrew MeltzerLead Sponsor
4 Previous Clinical Trials
804 Total Patients Enrolled
BioMérieuxIndustry Sponsor
58 Previous Clinical Trials
41,870 Total Patients Enrolled
1 Trials studying Viral Infections
200 Patients Enrolled for Viral Infections
Andrew Meltzer, MDPrincipal InvestigatorClinical Research Director, Department of Emergency Medicine
1 Previous Clinical Trials
24 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger